RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis

详细信息    查看全文

• 作者：Inga Peters (1)
  Kristina Rehmet (1)
  Nadine Wilke (2)
  Markus A Kuczyk (3)
  J?rg Hennenlotter (3)
  Tyark Eilers (1)
  Stefan Machtens (1)
  Udo Jonas (1)
  Jürgen Serth (1)
  
• 刊名：Molecular Cancer
• 出版年：2007
• 出版时间：December 2007
• 年：2007
• 卷：6
• 期：1
• 全文大小：1524KB
• 参考文献：1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. / CA Cancer J Clin 1999,49(1):8-1, 1. CrossRef
  2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. / CA Cancer J Clin 2005,55(1):10-0. CrossRef
  3. Thoenes W, Storkel S, Rumpelt HJ: Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. / Pathol Res Pract 1986,181(2):125-43.
  4. Zbar B, Brauch H, Talmadge C, Linehan M: Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. / Nature 1987,327(6124):721-24. CrossRef
  5. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, / et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. / Nat Genet 1994,7(1):85-0. CrossRef
  6. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, / et al.: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. / Cancer Res 1994,54(11):2852-855.
  7. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, / et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. / Proc Natl Acad Sci U S A 1994,91(21):9700-704. CrossRef
  8. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G, Zabarovsky ER: The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. / Proc Natl Acad Sci U S A 2001,98(13):7504-509. CrossRef
  9. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER: Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. / Cancer Res 2001,61(19):7277-281.
  10. Yoon JH, Dammann R, Pfeifer GP: Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. / Int J Cancer 2001,94(2):212-17. CrossRef
  11. Gonzalgo ML, Yegnasubramanian S, Yan G, Rogers CG, Nicol TL, Nelson WG, Pavlovich CP: Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. / Clin Cancer Res 2004,10(21):7276-283. CrossRef
  12. Agathanggelou A, Cooper WN, Latif F: Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. / Cancer Res 2005,65(9):3497-508. CrossRef
  13. Mathe E: RASSF1A, the new guardian of mitosis. / Nat Genet 2004,36(2):117-18. CrossRef
  14. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK, Lee H, Choi N, Kim J, Kim H, Kim JW, Choi EJ, Kirschner MW, Lim DS: The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. / Nature cell biology 2004,6(2):129-37. CrossRef
  15. Dallol A, Cooper WN, Al-Mulla F, Agathanggelou A, Maher ER, Latif F: Depletion of the Ras association domain family 1, isoform A-associated novel microtubule-associated protein, C19ORF5/MAP1S, causes mitotic abnormalities. / Cancer Res 2007,67(2):492-00. CrossRef
  16. Dallol A, Agathanggelou A, Tommasi S, Pfeifer GP, Maher ER, Latif F: Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. / Cancer Res 2005,65(17):7653-659.
  17. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, Tsark WM, Wilczynski SP, Li J, You M, Pfeifer GP: Tumor susceptibility of Rassf1a knockout mice. / Cancer Res 2005,65(1):92-8.
  18. Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T: Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma. / Oncol Rep 2004,12(4):805-10.
  19. Waki T, Tamura G, Sato M, Motoyama T: Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. / Oncogene 2003,22(26):4128-133. CrossRef
  20. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE, Cairns P: Promoter hypermethylation profile of kidney cancer. / Clin Cancer Res 2004,10(12 Pt 1):3972-979. CrossRef
  21. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. / Nat Genet 2000,25(3):315-19. CrossRef
  22. Yan PS, Shi H, Rahmatpanah F, Hsiau TH, Hsiau AH, Leu YW, Liu JC, Huang TH: Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. / Cancer Res 2003,63(19):6178-186.
  23. Issa JP: Age-related epigenetic changes and the immune system. / Clin Immunol 2003,109(1):103-08. CrossRef
  24. Nakagawa H, Nuovo GJ, Zervos EE, Martin EW Jr., Salovaara R, Aaltonen LA, de la Chapelle A: Age-related hypermethylation of the 5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. / Cancer Res 2001,61(19):6991-995.
  25. Shen L, Kondo Y, Hamilton SR, Rashid A, Issa JP: P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. / Gastroenterology 2003,124(3):626-33. CrossRef
  26. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. / Proc Natl Acad Sci U S A 1996,93(18):9821-826. CrossRef
  27. Ikuerowo SO, Kuczyk MA, Mengel M, van der Heyde E, Shittu OB, Vaske B, Jonas U, Machtens S, Serth J: Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. / Int J Cancer 2006,119(4):867-74. CrossRef
  28. von Wasielewski R, Mengel M, Gignac S, Wilkens L, Werner M, Georgii A: Tyramine amplification technique in routine immunohistochemistry. / J Histochem Cytochem 1997,45(11):1455-459.
  29. Mengel M, Werner M, von Wasielewski R: Concentration dependent and adverse effects in immunohistochemistry using the tyramine amplification technique. / Histochem J 1999,31(3):195-00. CrossRef
  30. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. / J Natl Cancer Inst 2001,93(9):691-99. CrossRef
  
• 作者单位：Inga Peters (1)
  Kristina Rehmet (1)
  Nadine Wilke (2)
  Markus A Kuczyk (3)
  J?rg Hennenlotter (3)
  Tyark Eilers (1)
  Stefan Machtens (1)
  Udo Jonas (1)
  Jürgen Serth (1)
  
  1. Department of Urology, Medizinische Hochschule Hannover, Hannover, Germany
  2. Department of Forensic Medicine, Medizinische Hochschule Hannover, Germany
  3. Department of Urology, Eberhard-Karls University, Tübingen, Germany
  
• ISSN：1476-4598

文摘

Background Epigenetic silencing of the RAS association domain family 1A (RASSF1A) tumor suppressor gene promoter has been demonstrated in renal cell carcinoma (RCC) as a result of promoter hypermethylation. Contradictory results have been reported for RASSF1A methylation in normal kidney, thus it is not clear whether a significant difference between RASSF1A methylation in normal and tumor cells of the kidney exists. Moreover, RASSF1A expression has not been characterized in tumors or normal tissue as yet. Results Using combined bisulfite restriction analysis (COBRA) we compared RASSF1A methylation in 90 paired tissue samples obtained from primary kidney tumors and corresponding normal tissue. Bisulfite sequence analysis was carried out using both pooled amplicons from the tumor and normal tissue groups and subclones obtained from a single tissue pair. Expression of RASSF1A was analyzed by the use of tissue arrays and immunohistochemistry. We found significantly increased methylation in tumor samples (mean methylation, 20%) compared to corresponding normal tissues (mean methylation, 11%; P < 0.001). Densely methylated sequences were found both in pooled and individual sequences of normal tissue. Immunohistochemical analysis revealed a significant reduced expression of RASSF1A in most of the tumor samples. Heterogeneous expression patterns of RASSF1A were detected in a subgroup of histologically normal tubular epithelia. Conclusion Our methylation and expression data support the hypothesis that RASSF1A is involved in early tumorigenesis of renal cell carcinoma.